Cue Biopharma Inc Цена / Продажи
Что обозначает Цена / Продажи в Cue Biopharma Inc?
Цена / Продажи Cue Biopharma Inc является 15.31
Какое определение для Цена / Продажи?
Соотношение цены и продаж - это цена акций компании по сравнению с её доходами.
The price to sales ratio, Price/Sales ratio, P/S ratio, or PSR, is a valuation metric for stocks. It is calculated by dividing the company's market cap by the revenue in the most recent year. It can also be calculated by dividing the per-share stock price by per-share revenue. The price to sales ratio is for trailing twelve months so the reported sales are for the four previous quarters. Longer time periods can be examined at times.
A smaller price to sales ratio is usually thought to be a better investment since the investor is paying less for each unit of sales. However, sales do not reveal the whole picture, as the company may be unprofitable with a low P/S ratio. Because of the limitations, this ratio is usually used only for unprofitable companies, since they don't have a price to earnings ratio (P/E ratio). The metric can be used to determine the value of a stock relative to its past performance. It may also be used to determine relative valuation of a sector or the market as a whole.
Price to sales ratios vary greatly between sectors, so they are most useful in comparing similar stocks within a sector or sub-sector. Comparing P/S ratios carries the implicit assumption that all firms in the comparison have an identical capital structure.
Цена / Продажи компаний в Health Care сектор на NASDAQ по сравнению с Cue Biopharma Inc
Что делает Cue Biopharma Inc?
cue biopharma is an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. we design biologics to engage and modulate the activity of disease-associated t cells in the patient’s body, offering significant therapeutic advantages while potentially minimizing or eliminating unwanted side effects. we believe our biologics allow us to target antigen-specific t cell populations in a variety of indications using a simple peptide exchange within previously-validated drug frameworks developed from the cue biologics platform. this flexibility could truncate the drug selection and development process, moving effective therapeutics from discovery to clinical validation more rapidly and cost efficiently than current industry standard timelines and costs. headquartered in kendall square, cambridge, ma, we are led by an experienced management team and sci
Компании с цена / продажи похож на Cue Biopharma Inc
- Dalal Street Investments имеет Цена / Продажи из 15.24
- MFA Inc имеет Цена / Продажи из 15.27
- APN Property имеет Цена / Продажи из 15.28
- P10 имеет Цена / Продажи из 15.28
- MPH Health Care AG имеет Цена / Продажи из 15.29
- Hermès International SCA имеет Цена / Продажи из 15.30
- Cue Biopharma Inc имеет Цена / Продажи из 15.31
- Maui Land & Pineapple Co имеет Цена / Продажи из 15.31
- Dunedin Income Growth Investment Trust Plc имеет Цена / Продажи из 15.32
- Lattice Semiconductor имеет Цена / Продажи из 15.32
- Mersana Therapeutics Inc имеет Цена / Продажи из 15.33
- Starwood European Real Estate Finance имеет Цена / Продажи из 15.33
- Wolfspeed Dl ,00125 имеет Цена / Продажи из 15.34